RxDoctor Payments Data

Hau Chieng, DO

Pulmonary Disease · Albany, NYNPI 1902290315

Payments from drug & device makers

$4,415in general payments, 2019–2025

Across 50 payments — averaging $88.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Astellas Pharma US Inc$535
  • Regeneron Healthcare Solutions, Inc.$524
  • Sanofi$479
  • Boehringer Ingelheim$426
  • Johnson & Johnson$312
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,12093%
  • Education$2957%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,415 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$127,095
Medicare patients
349
Services billed
1,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter534$654,701
Dupixent PenDupilumab13$53,333
TezspireTezepelumab-Ekko12$52,652
Breo ElliptaFluticasone/Vilanterol56$47,773
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$44,711
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$37,499
Stiolto RespimatTiotropium Br/Olodaterol Hcl36$21,666
Advair HfaFluticasone Propion/Salmeterol27$18,338
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate36$13,777
Fluticasone-SalmeterolFluticasone Propion/Salmeterol67$12,269
Albuterol Sulfate HfaAlbuterol Sulfate290$10,001
DuleraMometasone/Formoterol12$9,166
Spiriva RespimatTiotropium Bromide18$8,908
SymbicortBudesonide/Formoterol Fumarate18$7,013
Bevespi AerosphereGlycopyrrolate/Formoterol Fum17$6,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,104$747,185637 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$125$104,11075 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$426$30,57454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →